Dyne Therapeutics Ownership | Who Owns Dyne Therapeutics?
Dyne Therapeutics Ownership Summary
Dyne Therapeutics is owned by 116.14% institutional investors, 0.25% insiders. T. rowe price investment management is the largest institutional shareholder, holding 18.73% of DYN shares. T. Rowe Price US Small-Cap Core Equity is the top mutual fund, with 4.24% of its assets in Dyne Therapeutics shares.
DYN Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Dyne Therapeutics | 116.14% | 0.25% | -16.39% |
| Sector | Healthcare Stocks | 247.07% | 12.15% | -159.22% |
| Industry | Biotech Stocks | 385.89% | 11.79% | -297.68% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| T. rowe price investment management | 30.91M | 18.73% | $686.56M |
| Janus henderson group | 13.65M | 10.63% | $247.43M |
| Blackrock | 7.39M | 9.11% | $260.69M |
| Blackrock funding, inc. /de | 14.47M | 8.75% | $233.14M |
| Vanguard group | 11.22M | 7.91% | $219.38M |
| Fmr | 11.15M | 6.74% | $179.57M |
| State street | 8.16M | 4.93% | $131.43M |
| Vanguard capital management | 7.55M | 4.56% | $121.67M |
| Orbis allan gray | 7.01M | 4.25% | $155.62M |
| Vanguard portfolio management | 4.69M | 2.84% | $75.58M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Mpm asset management | 682.38K | 19.40% | $8.63M |
| Fcpm iii services b.v. | 3.85M | 11.39% | $85.47M |
| Atlas venture life science advisors | 3.44M | 8.78% | $55.43M |
| Palo alto investors lp | 1.65M | 5.06% | $36.59M |
| University of wisconsin foundation | 313.56K | 3.46% | $5.05M |
| Saturn v capital management | 1.06M | 3.37% | $23.49M |
| Bioimpact capital | 1.92M | 2.60% | $42.69M |
| Tcg crossover management | 4.62M | 2.46% | $102.50M |
| Logos global management lp | 2.55M | 2.44% | $56.64M |
| Lion point capital, lp | 18.00K | 1.91% | $399.78K |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Blackrock funding, inc. /de | 14.47M | 0.00% | 2.07M |
| Blackrock | 7.39M | 0.01% | 2.00M |
| Paradigm biocapital advisors lp | 1.90M | 0.68% | 1.90M |
| Price t rowe associates inc /md/ | 3.94M | 0.01% | 1.61M |
| Vanguard group | 11.22M | 0.00% | 1.46M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Ra capital management | - | - | -9.71M |
| Atlas venture life science advisors | 3.44M | 8.78% | -3.36M |
| Holocene advisors, lp | - | - | -2.35M |
| Perceptive advisors | 2.69M | 0.90% | -1.98M |
| Jefferies financial group | - | - | -1.80M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Paradigm biocapital advisors lp | 1.90M | 0.68% | 1.90M | $24.02M |
| Novo | 960.39K | 1.24% | 960.39K | $21.33M |
| Nantahala capital management | 382.44K | 0.19% | 382.44K | $6.16M |
| Granahan investment management | 338.56K | 0.27% | 338.56K | $7.52M |
| Jones hill capital lp | 300.90K | 0.82% | 300.90K | $4.85M |
Sold Out
| Holder | Change |
|---|---|
| Dunhill financial | -1.00 |
| Hfm investment advisors | -3.00 |
| Nelson, van denburg & campbell wealth management group | -9.00 |
| Creative financial designs inc /adv | -10.00 |
| J.safra asset management | -11.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | 253 | 7.20% | 191,678,138 | 2.03% | 116 | 0.90% | 140 | -2.78% | 74 | 21.31% |
| Mar 31, 2026 | 229 | -4.58% | 186,215,369 | 4.65% | 144 | 0.92% | 139 | -9.74% | 60 | 7.14% |
| Dec 31, 2025 | 48 | -77.78% | 17,667,612 | -88.66% | 12 | 0.07% | 33 | -77.40% | 8 | -80.49% |
| Sep 30, 2025 | 56 | -72.00% | 16,926,024 | -86.84% | 14 | 0.12% | 39 | -66.95% | 9 | -82.69% |
| Jun 30, 2025 | 198 | -5.71% | 128,546,973 | 5.45% | 112 | 0.92% | 116 | -10.08% | 52 | 15.56% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| T. Rowe Price US Small-Cap Core Equity | 7.00M | 4.24% | -7.60K |
| T. Rowe Price Small-Cap Stock | 7.90M | 4.23% | 491.94K |
| Vanguard Health Care Inv | 6.11M | 3.27% | 6.11M |
| Vanguard MStar Total Stk Mkt Idx Invest | 5.27M | 2.83% | 18.00K |
| Vanguard Total Stock Mkt Idx Inv | 4.47M | 2.71% | -242.06K |
| T. Rowe Price Small-Cap Value | 4.76M | 2.55% | 148.60K |
| State Street® SPDR® S&P® Biotech ETF | 4.67M | 2.49% | 122.13K |
| Vanguard Morn Total Stk Mkt Idx Investor | 4.47M | 2.40% | -242.06K |
| Vanguard US Total Market Shares ETF | 2.65M | 2.35% | 2.40K |
| T. Rowe Price Instl Small-Cap Stock | 4.25M | 2.28% | 205.98K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Nov 13, 2026 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | $3.89K |
| Nov 13, 2026 | Kerr Douglas | Head of R&D and CMO | Sell | $43.80K |
| Nov 13, 2026 | Lucera Erick | Chief Financial Officer | Sell | $33.49K |
| Oct 02, 2026 | Posner Brian S | - | Buy | $40.00K |
| Sep 08, 2026 | Friedl-Naderer Johanna | Chief Commercial Officer | Sell | $3.49K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q4 | 1 | - |
| 2026 Q3 | - | 27 |
| 2026 Q2 | 4 | 84 |
| 2026 Q1 | 3 | 8 |
| 2025 Q4 | - | 3 |
DYN Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools